Immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine under different vaccination intervals

• Main Authors: Xiao-Juan Yu (Author), Juan Li (Author), Zhi-Jie Lin (Author), Hui Zhao (Author), Bi-Zhen Lin (Author), You-Lin Qiao (Author), Yue-Mei Hu (Author), Li-Hui Wei (Author), Rong-Cheng Li (Author), Wei-Dan Huang (Author), Ting Wu (Author), Shou-Jie Huang (Author), Chang-Gui Li (Author), Hui-Rong Pan (Author), Jun Zhang (Author)
• Format: Book
• Published: Taylor & Francis Group, 2020-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

A new Escherichia coli-produced human papillomavirus (HPV)-16/18 vaccine has been shown to be safe and highly efficacious and was recently licensed in China. As a post hoc analysis of the phase III trial, this study aimed to assess the impact of vaccination time deviations on the specific antibody r...